Earningsreport

Q1/2024 3/31/2024 EPS -0.720 ZacksConsensus -0.900 ActVsEst 0.180 - Beat

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com